



BLISS GVS PHARMA LIMITED

Registered Office: 102, Hyde Park, Sakivihar Road, Andheri (East), Mumbai - 400 072.

AUDITED FINANCIAL RESULTS FOR THE QUARTER / YEAR ENDED 31.03.2014

PART-I

(₹ in Lacs)

SR. No.	PARTICULARS	STANDALONE					CONSOLIDATED	
		QUARTER ENDED			YEAR ENDED	YEAR ENDED	YEAR ENDED	YEAR ENDED
		31.03.2014 (AUDITED)*	31.12.2013 (UNAUDITED)	31.03.2013 (AUDITED)	31.03.2014 (AUDITED)	31.03.2013 (AUDITED)	31.03.2014 (AUDITED)	31.03.2013 (AUDITED)
1	Income From Operations							
	(a) Net Sales (Net of Excise Duty)	5,373.14	5,885.77	10,012.71	28,349.25	34,810.82	33,973.26	39,083.24
	(b) Other Operating Income	175.84	114.98	250.70	696.43	557.50	713.58	579.30
	Total Income from Operations (Net)	5,548.97	6,000.75	10,263.41	29,045.68	35,368.32	34,686.84	39,662.54
2	Expenses							
	a) Consumption of Raw Materials	2,969.99	2,206.27	5,588.20	13,517.82	18,800.30	15,554.09	20,082.50
	b) Purchase of Traded Goods	529.50	-	52.50	1,030.40	360.28	1,551.65	872.44
	c) (Increase)/Decrease in Stock in Trade	(369.38)	165.13	(94.65)	60.57	(511.72)	(42.67)	(623.17)
	d) Employee Benefit Expenses	340.48	323.94	272.90	1,292.61	987.07	2,346.29	1,507.85
	e) Depreciation / Amortisation	71.57	128.04	119.71	446.16	442.78	1,068.18	602.54
	f) Other Expenditure	1,363.94	1,370.55	2,695.71	6,314.46	5,654.21	7,932.83	6,707.28
	Total Expenses	4,906.09	4,193.93	8,634.37	22,662.02	25,732.90	28,410.37	29,149.44
3	Profit from Operations Before other Income & Finance Cost & Exceptional Items (1-2)	642.88	1,806.82	1,629.04	6,383.66	9,635.42	6,276.47	10,513.10
4	Other Income	90.01	145.46	731.82	2,789.81	1,503.28	2,577.58	1,406.98
5	Profit from ordinary activities before Finance Cost (3+4)	732.89	1,952.28	2,360.86	9,173.47	11,138.70	8,854.05	11,920.08
6	Finance Cost	309.44	220.86	221.13	943.63	655.46	1,798.23	971.84
7	Profit from ordinary activities after Finance Cost but before Exceptional Items (5-6)	423.45	1,731.42	2,139.73	8,229.84	10,483.24	7,055.82	10,948.24
8	Exceptional Items	-	-	-	-	-	-	-
9	Profit from Ordinary Activities Before Tax (7-8)	423.45	1,731.42	2,139.73	8,229.84	10,483.24	7,055.82	10,948.24
10	Tax Expense (Including Deferred Tax)	272.00	668.58	1,569.28	2,837.19	4,815.03	2,952.67	4,989.78
11	Net Profit for the Period (9-10)	151.45	1,062.84	570.45	5,392.65	5,668.21	4,103.15	5,958.46
12	Minority Interest	-	-	-	-	-	(3.98)	(186.45)
13	Net Profit after Tax & Minority Interest (11-12)	151.45	1,062.84	570.45	5,392.65	5,668.21	4,099.17	5,772.01
14	Paid-Up Equity Capital	1,031.47	1,031.47	1,031.47	1,031.47	1,031.47	1,031.47	1,031.47
15	Reserves Excluding Revaluation Reserve (As Per Balance Sheet)	-	-	-	30,452.64	24,842.03	27,656.65	24,769.10
16	Basic and Diluted EPS (Not Annualised)	0.15	1.03	0.55	5.23	5.50	3.97	5.60

STATEMENT OF ASSETS AND LIABILITIES AS AT 31ST MARCH, 2014.

(₹ in Lacs)

SR. No.	PARTICULARS	STANDALONE		CONSOLIDATED	
		Mar-14	Mar-13	Mar-14	Mar-13
I.	Equity and Liabilities				
1	Shareholders' Funds :				
	(i) Share Capital	1,031.47	1,031.47	1,031.47	1,031.47
	(ii) Reserves and Surplus	30,452.64	24,842.04	27,656.65	24,769.10
	(iii) Money received against Share Warrants	-	-	-	-
	Sub-total - Shareholders' Funds	31,484.11	25,873.51	28,688.12	25,800.57
2	Minority Interest	-	-	1016.26	1,379.87
3	Non-Current Liabilities				
	(i) Long Term Borrowings	4,513.54	5,367.81	8,758.83	9,129.84
	(ii) Deferred Tax Liabilities(Net)	619.80	436.68	695.79	487.94
	(iii) Other Long Term Liabilities	-	-	-	-
	(iv) Long Term Provisions	79.23	73.81	79.23	73.81
	Sub-total - Non-Current Liabilities	5,212.57	5,878.30	9,533.85	9,691.59
4	Current Liabilities				
	(i) Short Term Borrowings	2,314.16	1,820.75	5,704.90	4,515.75
	(ii) Trade Payables	5,898.97	9,242.53	8,235.44	11,815.12
	(iii) Other Current Liabilities	2,851.53	1,381.71	4,211.63	2,444.69
	(iv) Short Term Provisions	878.11	1,422.23	888.36	1,443.50
	Sub-total - Current Liabilities	11,942.77	13,867.22	19,040.33	20,219.06
	Total	48,639.45	45,619.03	58,278.56	57,091.09
II.	Assets				
1	Non-current Assets				
	(a) Fixed Assets	5,783.71	4,944.14	21,764.00	16,887.92
	(b) Non-current Investments	1,922.53	1,922.02	1.01	1.01
	(c) Deferred Tax Assets	-	-	-	-
	(d) Long Term Loans and Advances	10,617.86	9,517.28	901.57	5,072.32
	(e) Other Non Current Assets	188.66	241.20	188.66	241.20
	Sub-total - Non-current Assets	18,512.76	16,624.64	22,855.24	22,202.45
2	Current Assets				
	(a) Current Investments	-	-	-	-
	(b) Inventories	2,122.89	2,458.45	3,253.04	3,252.33
	(c) Trade Receivables	18,353.25	21,821.11	21,502.59	24,464.43
	(d) Cash and Bank Balances	7,412.07	3,081.60	8,037.21	5,035.00
	(e) Short Term Loans and Advances	1,552.04	1,207.32	2,367.83	1,745.36
	(f) Other Current Assets	686.44	425.91	262.65	391.52
	Sub-total - Current Assets	30,126.69	28,994.39	35,423.32	34,888.64
	Total	48,639.45	45,619.03	58,278.56	57,091.09

Note:

- The company operates primarily in the Pharmaceutical Business and hence has only one reportable segment.
- The consolidated results includes the Audited Financial Results of parent company, the subsidiaries namely Bliss GVS International Pte Ltd (100% Holding), Bliss Indasi Life Sciences Pvt Ltd (51% Holding), Bliss GVS Clinic Healthcare Pte Ltd (100% Holding), Kremint Pharma Pvt. Ltd. (70% Holding), Lifeon Labs Pvt Ltd (51%) & its step down subsidiaries
- Tax Expenses for the Quarter and Year Ended March 31st, 2014 includes short provision for earlier years Rs. 170.00 Lacs and Quarter and Year Ended March 31st, 2013 includes short provision of Earlier Years of Rs. 1422.66 Lacs (Including Mat Reversal).
- The Board has Recommended a dividend of 50% i.e Rs. 0.50 per Equity Share for the year Ended 31st March 2014.
- Other Income for Year Ended 31st March 2014 includes Realised Exchange gain of Rs. 2175.05 Lacs (Previous Year Ended Rs. 1106.59 Lacs) and Unrealised Exchange Loss (Net) of Rs. 78.59 Lacs. (Previous Year Ended Rs. 242.89 Lacs).
- *6. The Figures for the Quarter Ended March 31st, 2014 and 2013 are the balancing figures between the Audited Figures in respect of the full Financial Year and the year to date published results for the nine months ended December 31st, 2013 and 2012.
- Previous Year/Period Figures are Regrouped/Rearranged wherever necessary.
- The above results were reviewed by the Audit committee & were there after approved by the Board at its Meeting held on May 26th 2014.

PART-II

SR. No.	PARTICULARS	STANDALONE					CONSOLIDATED	
		QUARTER ENDED			YEAR ENDED	YEAR ENDED	YEAR ENDED	YEAR ENDED
		31.03.2014 (AUDITED)*	31.12.2013 (UNAUDITED)	31.03.2013 (AUDITED)	31.03.2014 (AUDITED)	31.03.2013 (AUDITED)	31.03.2014 (AUDITED)	31.03.2013 (AUDITED)
A	Particulars of Shareholding							
1	Aggregate of Non-promoter Shareholding							
	- No. of Shares (face Value Rs.1/- Each)	36156842	36156842	36186842	36156842	36186842	36156842	36186842
	- Percentage of Shareholding (%)	35.05	35.05	35.08	35.05	35.08	35.05	35.08
2	Promoter and Promoter group Shareholding							
	A) Pledge / Encumbered							
	- No. of Shares (Face Value Re.1/- Each)	-	-	-	-	-	-	-
	- Percentage of Shares (As % of the Total Share Holding of Promoter & Promoter Group)	-	-	-	-	-	-	-
	- Percentage of Shares (as % of the Total Share Capital of The Company)	-	-	-	-	-	-	-
	B) Non - Encumbered							
	- No. of Shares (Face Value Re.1/- Each)	66989830	66989830	66959830	66989830	66959830	66989830	66959830
	- Percentage of Shares (As % of the Total Share Holding of Promoter & Promoter Group)	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (As % of the Total Share Capital of The Company)	64.95	64.95	64.92	64.95	64.92	64.95	64.92

SR. No.	PARTICULARS	Quarter Ended 31st March 2014	
B	Investor Complaints		
	Pending at the beginning of the quarter	-	-
	Received during the quarter	1	1
	Disposed off during the quarter	1	1
	Remaining unsolved at the end of the quarter	-	-

FOR BLISS GVS PHARMA LIMITED
SD/-

Place : Mumbai
Date : 26th May 2014

S. N. KAMATH
MANAGING DIRECTOR